Gene therapy for acute diseases

Molecular Therapy

Volumn 4, Issue 6, 2001, Pages 515-524

  Factor, Phillip ^a,b  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute lung injury; Anticoagulation; Asthma; Gene therapy; Seizure myocardial infarction; Stroke; Subarachnoid hemorrhage

Indexed keywords

ADENOSINE; ALPHA 1 ANTITRYPSIN; ANTIINFECTIVE AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL RESPONSE MODIFIER; CALCITONIN GENE RELATED PEPTIDE; CYTOTOXIN; DNA; ELAFIN; ELASTASE INHIBITOR; GENE PRODUCT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCOSE TRANSPORTER; GLUTAMATE DECARBOXYLASE; HIRUDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; KERATINOCYTE GROWTH FACTOR; NITRIC OXIDE SYNTHASE; NUCLEOTIDE; PROTEIN BCL 2; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VASCULOTROPIN; VASODILATOR AGENT;

ACUTE DISEASE; ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTHMA; CELL FUNCTION; CONTROLLED STUDY; DRUG MECHANISM; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HUMAN; INFECTION; LUNG EDEMA; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; RAT; REVIEW; SEIZURE; STROKE; SUBARACHNOID HEMORRHAGE; THROMBOSIS; TRANSGENE;

ANIMALIA;

EID: 0035661253     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0504     Document Type: Review

References (128)

1. Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: Comparison of VSV-G and amphotropic for hepatic gene transfer
2. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results
3. Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: Comparison to adenovirus
4. 1 subunit
5. 1 subunit gene improves alveolar fluid clearance and survival in hyperoxic rats
6. +-ATPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedema
7. 2-Adrenergic receptor overexpression increases alveolar fluid clearance and responsiveness to endogenous catecholamines in rat
8. Use of perfluorochemical liquid allows earlier detection of gene expression and use of less vector in normal lung and enhances gene expression in acutely injured lung
9. Acute hyperoxic lung injury does not impede adenoviral-mediated alveolar gene transfer
10. In vitro and in vivo transfer and expression of human surfactant SP-A and SP-B associated protein cDNAs mediated by replication deficient, recombinant adenoviral vector
11. Aerosol and intravenous transfection of human α 1-antitrypsin gene to lungs of rabbits
12. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection
13. Gene therapy for oxidant injury-related diseases: Adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury
14. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury
15. Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis
16. Manganese superoxide dismutase (MnSOD) plasmid/liposome pulmonary radioprotective gene therapy: Modulation of irradiation-induced mRNA for II-I, TNF-α, and TGF-β correlates with delay of organizing alveolitis/fibrosis
17. Effect of adenovector-mediated gene transfer of keratinocyte growth factor on the proliferation of alveolar type II cells in vitro and in vivo
18. Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and β-agonist therapy
19. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats
20. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes
21. Adenovirally mediated gene transfer of functional human tissue-type plasminogen activator to murine lungs
22. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
23. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema
24. Catenin-dependent and -independent functions of vascular endothelial cadherin
25. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats
26. Protection of rabbit lungs from endotoxin injury by in vivo hyperexpression of the prostaglandin G/H synthase gene
27. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo
28. The glucocorticoid receptor gene as a candidate for gene therapy in asthma
29. Mucosal IFN-γ gene transfer inhibits pulmonary allergic responses in mice
30. Systemic and local interferon γ gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice
31. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity
32. II-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyperreactivity
33. CD4(+) T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation
34. Targeted transgenic expression of β(2)-adrenergic receptors to type II cells increases alveolar fluid clearance
35. Modification of the β 2-adrenergic receptor to engineer a receptor-effector complex for gene therapy
36. DNA antisense therapy for asthma in an animal model
37. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma
38. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction
39. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction
40. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits
41. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo
42. Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo
43. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis
44. Reduction in myocardial apoptosis associated with overexpression of heat shock protein 70
45. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion
46. Defective herpes simplex virus vectors expressing the rat brain glucose transporter protect cultured neurons from necrotic insults
47. An adenoviral vector expressing the glucose transporter protects cultured striatal neurons from 3-nitropropionic acid
48. Overexpression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke
49. A herpes simplex virus vector overexpressing the glucose transporter gene protects the rat dentate gyrus from an antimetabolite toxin
50. Neuroprotective effects of an adenoviral vector expressing the glucose transporter: A detailed description of the mediating cellular events
51. Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury after transient middle cerebral artery occlusion in rats
52. Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia
53. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo
54. Gene therapies that enhance hippocampal neuron survival after an excitotoxic insult are not equivalent in their ability to maintain synaptic transmission
55. Sparing of neuronal function postseizure with gene therapy
56. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus
57. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus
58. Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy
59. Calbindin D28K gene transfer via herpes simplex virus amplicon vector decreases hippocampal damage in vivo following neurotoxic insults
60. Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-ss1 expression
61. Attenuation of ischemic inflammatory response in mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist
62. Attenuation of intracerebral hemorrhage and thrombin-induced brain edema by overexpression of interleukin-1 receptor antagonist
63. Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke
64. Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss
65. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system
66. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: Potential for the treatment of neurological diseases
67. Lipofectin-facilitated transfer of cholecystokinin gene corrects behavioral abnormalities of rats with audiogenic seizures
68. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy
69. Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: Implications for a gene therapy approach to epilepsy
70. Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: Prospects for gene therapy in epilepsy
71. Gene transfer to cerebral blood vessels after subarachnoid hemorrhage
72. Gene transfer of calcitonin gene-related peptide prevents vaso-constriction after subarachnoid hemorrhage
73. Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage
74. Decoy administration of NF-κB into the subarachnoid space for cerebral angiopathy
75. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery after experimental subarachnoid hemorrhage
76. Adenovirus-mediated gene transfer to human cerebral arteries
77. Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model
78. Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase
79. Local adenovirus-mediated delivery of hirudin in a rabbit arterial injury model
80. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury
81. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries
82. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit
83. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor
84. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model
85. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene
86. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta
87. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
88. Gene therapy for vascular smooth muscle cell proliferation after arterial injury
89. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product
90. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
91. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo
92. Enhancement of neointima formation with tissue-type plasminogen activator
93. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries
94. Thrombomodulin overexpression to limit neointima formation
95. 1998 ARRS President's Award. The potential of in vivo vascular tissue engineering for the treatment of vascular thrombosis: A preliminary report. American Roentgen Ray Society
96. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: Effects on vascular smooth muscle cell differentiation and superoxide production
97. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins
98. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein
99. Locally applied antisense oligonucleotide to proliferating cell nuclear antigen inhibits intimal thickening in experimental vein grafts
100. bg inhibitor suggests a major role of G protein signaling in lesion development
101. Adenoviral-mediated inhibition of G βγ signaling limits the hyperplastic response in experimental vein grafts
102. Adenovirus-mediated transfer of a recombinant human α1-antitrypsin cDNA to human endothelial cells
103. Adenoviral-mediated gene transfer in human and animal vein grafts using clinically relevant exposure times, pressures, and viral concentrations
104. Calcium phosphate precipitates augment adenovirus-mediated gene transfer to blood vessels in vitro and in vivo
105. Cationic polymer and lipids enhance adenovirus-mediated gene transfer to rabbit carotid artery
106. Thrombus generation after adenovirus-mediated gene transfer into atherosclerotic arteries
107. Vasomotor dysfunction early after exposure of normal rabbit arteries to an adenoviral vector
108. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: Impact on transgene expression and endothelial function
109. Improved adenoviral vector for vascular gene therapy: Beneficial effects on vascular function and inflammation
110. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin
111. Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation
112. Adenoviral vector-mediated gene transfer into sheep arteries using a double-balloon catheter
113. The Dispatch catheter as a delivery tool for arterial gene transfer
114. Percutaneous adenoviral gene transfer into porcine coronary arteries: Is catheter-based gene delivery adapted to coronary circulation?
115. Adenoviral vector-mediated interleukin-10 expression in vivo: Intramuscular gene transfer inhibits cytokine responses in endotoxemia
116. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis
117. Interleukin-10 gene therapy mediated amelioration of bacterial pneumonia
118. Interleukin-10 gene transfer improves the survival rate of mice inoculated with Escherichia coli
119. Adenoviral delivery of human and viral IL-10 in murine sesis
120. Lps(d)/Ran of endotoxin-resistant C3H/HeJ mice is defective in mediating lipopolysaccharide endotoxin responses
121. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense
122. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative pneumonia
123. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor
124. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus
125. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection
126. Transient transgenic expression of γ interferon promotes Legionella pneumophila clearance in immunocompetent hosts
127. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia
128. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-γ gene